| Names | |
|---|---|
| Preferred IUPAC name | 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole |
| Other names | Losec Prilosec Prilosec OTC Omez Zegerid Antra Omecat |
| Pronunciation | /əˈmiː.prə.zəʊl/ |
| Identifiers | |
| CAS Number | 73590-58-6 |
| Beilstein Reference | Beilstein Reference: 607324 |
| ChEBI | CHEBI:7762 |
| ChEMBL | CHEMBL953 |
| ChemSpider | 82534 |
| DrugBank | DB00338 |
| ECHA InfoCard | 41e2702b-2fbe-4c97-8708-1df8041be9e0 |
| EC Number | H20030128 |
| Gmelin Reference | Gmelin Reference: 286314 |
| KEGG | D08365 |
| MeSH | D000077151 |
| PubChem CID | 4594 |
| UNII | L16LL9208G |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | EOC8V5WX5Z |
| Properties | |
| Chemical formula | C17H19N3O3S |
| Molar mass | 345.42 g/mol |
| Appearance | Hard capsule, with a yellow cap and a white body, containing white or off-white enteric-coated pellets. |
| Odor | Odorless |
| Density | 0.25 g/capsule |
| Solubility in water | Practically insoluble in water |
| log P | 2.23 |
| Acidity (pKa) | pKa = 4.0 |
| Basicity (pKb) | 7.88 |
| Dipole moment | 0.00 D |
| Pharmacology | |
| ATC code | A02BC01 |
| Hazards | |
| Main hazards | Main hazards: Gastrointestinal disturbances, headache, dizziness, skin rash, hypersensitivity reactions |
| GHS labelling | GHS labelling: Not classified as hazardous according to GHS |
| Pictograms | 💊⚠️🚫🥤🍊 |
| Precautionary statements | Special precaution should be taken in patients with severe liver dysfunction. |
| Lethal dose or concentration | LD50 (rat, oral): > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Omeprazole Enteric-coated Capsules: "LD50 (rat, oral) > 2,000 mg/kg |
| NIOSH | Y3A424W8HT |
| REL (Recommended) | 20 mg once daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Esomeprazole Lansoprazole Pantoprazole Rabeprazole Dexlansoprazole |
| Property | Manufacturer’s Commentary & Technical Perspective |
|---|---|
| Product Name & IUPAC Name |
Product Name: Omeprazole Enteric-coated Capsules IUPAC Name: 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole In production, IUPAC nomenclature typically appears in analytical documents but is not on commercial packaging. Capsule forms require strict application of the core API IUPAC confirmed by NMR and HPLC batch release data. |
| Chemical Formula |
C17H19N3O3S The molecular formula represents the free base form. Enteric-coated final dosage forms include this active moiety along with specific excipients and protective coatings chosen based on compatibility studies during process development. |
| Synonyms & Trade Names |
Synonyms: Omeprazolum, Losec (trade name), Prilosec Capsule formulations may differ by region—trade names and registered designations are market-dependent. Regulatory submissions require reference to the API synonym list for pharmacopoeial alignment. |
| HS Code & Customs Classification |
HS Code: 3004.90 Enteric-coated oral dosage forms fall under preparations containing hormones or other defined therapeutic uses. Customs classification varies between jurisdictions—proper documentation supports batch traceability and tariff control. Final product regulatory descriptors should align with customs declarations for both bulk and finished forms; internal compliance verifies code application prior to export. |
Omeprazole enteric-coated capsules represent a multi-step manufacturing process, starting from purification and analysis of the active ingredient through to enteric-coating application and final assembly. Capsule performance, including resistance to gastric fluid and release profile, depends on grade-specific excipient selection and uniformity of the coating process.
Batch-to-batch consistency relies on rigorous raw material selection, in-process pH and solvent controls, and strict environmental monitoring during granulation and encapsulation. Omeprazole's known sensitivity to moisture and light requires design of material flows and packaging lines to minimize exposure. Customer specifications can drive changes in capsule shell materials, colorants, imprinting, and blister packaging configuration; these variables are controlled based on end-market compliance.
Impurity profile management centers on both API synthesis route and downstream capsule production, with each stage validated for leachable and residual solvent contaminants according to pharmacopeial and internal limits. The final release standard is subject to documented internal quality control criteria and export market registration requirements, updated as regulatory standards evolve.
Omeprazole appears as a white or off-white crystalline powder, uncoated or as coated pellets within a hard gelatin capsule. Particle morphology changes with batch granulation and coating process. The crystalline form has no significant odor. Melting point profiles can show minor variance based on polymorphism and residual solvent content; boiling point is not relevant due to decomposition before boiling. Flash point and density data remain process-limited, relevant primarily for bulk handling, less so for encapsulated material.
Omeprazole degrades under acidic and high-moisture conditions, which drives the need for enteric-coating in final dosage design. The core remains sensitive to light and elevated temperatures, and can react with oxidizing agents. Reactive impurities typically arise from incomplete coating or interaction with excipient metals. Stability is formulation- and packaging-dependent, with grade-specific profiles tailored for different regional regulatory or shelf-life needs.
Solubility remains low in aqueous environments, especially under neutral pH, but increases significantly in alkaline media. In industrial practice, solution preparation methods adapt to the intended final form: solvent selection focuses on maintaining the desired polymorphic form and limiting degradation during processing. For in-process testing, dissolution follows pharmacopeial buffers as per batch protocol.
Omeprazole capsules are produced in several grades, with the main differentiators revolving around potency, residual solvents, heavy metals, and microbiological controls. Commercial and pharmaceutical grades follow separate test frequencies and acceptance criteria.
Process impurities primarily include related benzimidazoles, sulfoxide and sulfide reduction products, and process-derived by-products. Impurity thresholds vary by regulatory jurisdiction and customer application, but internal specifications define strict upper limits to fit with international pharmacopeia and MAH requirements. Each batch is subject to HPLC or GC quantitation for both known and unknown impurities. The setup and thresholds tie closely to the synthesis route and purification efficiency.
Quality control applies validated chromatographic, spectrophotometric, and dissolution tests based on latest pharmacopeial or customer-agreed protocols. Each analytical method is maintained and revalidated according to instrument drift and method transfer status. Sampling and batch release standards are updated per process change or market feedback.
Selection focuses on high-purity 2-mercaptobenzimidazole and p-Methoxyphenylacetonitrile, with solvent grades and excipients audited for trace contaminants. Supplier approval includes multi-year validation for consistency in particle size, moisture, and impurity carryover.
Omeprazole production typically involves a sequential methylation and sulfoxidation route. The process alternates between organic and aqueous phases for controlled granulation, followed by pH-sensitive coating steps. Synthesis parameters, including temperature and reaction time, respond to upstream lot impurities and downstream handling constraints. Choice of oxidant and solvent varies based on scale, with regional sites adapting based on infrastructure and regulatory restrictions.
Key control points include sulfoxidation selectivity, control of exotherm during methylation, and real-time monitoring of coating integrity by in-process inspection. High-shear granulation minimizes polymorph variability. Purification focuses on both crystallization and filtration, tuning for batch-to-batch consistency. Yield and purity optimization frequently involve process stepwise feedback from analytical monitoring.
Every lot undergoes content uniformity, degradation profiling, moisture assessment, and microbiological screening. Release specification links to customer registration and market requirements, with re-sampling mandated upon any deviation. Batch records document process controls, deviations, and full traceability, reviewed by QA prior to any batch disposition.
In production, omeprazole primarily undergoes sulfoxidation and methylation. Under storage or misuse, hydrolytic cleavage and acid-catalyzed decomposition can occur, leading to discoloration or loss of potency.
Catalyst, temperature, and solvent selection depend on the specific reactor and scale. For laboratory scale, oxygen or hydrogen peroxide serve as oxidants; for large-scale, optimized oxidant concentration and reaction time control side product profiles. Solvent use is adjusted to minimize residual toxicity and maximize process safety.
Downstream potential includes synthesis of structural analogues for related proton pump inhibitors, but industrially, most side reactions are restricted due to tight regulatory controls. Modification potential focuses on excipient compatibility for new dosage formats, not major chemical derivative production.
Controlled temperature and humidity are crucial, with light-avoidant packaging standard for all finished goods. Nitrogen blanketing or low-oxygen headspace is used for bulk intermediate storage when required, tailored to prevent oxidative degradation. Each packaging system matches the moisture and reactivity profile of the batch.
Hard gelatin capsules and bespoke blister foils dominate, with ongoing assessment of compatibility with changing excipient grades and novel stabilizer systems. Compatibility checks include leachable and extractable screening for new packaging systems.
Shelf life parameters are supported by ongoing stability studies. Degradation indicators include color shifts, caking, or changes in dissolution profile. Quality retains the right to revise expiration intervals if trending or market surveillance signals change in performance.
Hazard category, if applicable, is designated based on the latest available data and regulatory submissions. Omeprazole does not fit acute toxicity categories for most intended uses, but dust generation and inhalation risk are reviewed for each production site.
Safety assessment includes review of sensitization, long-term exposure, and possible reactivity with cleaning and production agents. Production areas deploy dust control and closed-transfer to minimize material exposure. Handling instructions are updated per ongoing workplace safety audits, with PPE recommendations reviewed site by site.
Available toxicity results show low acute hazard in animal studies; chronic studies guide process containment practices. Site-specific exposure controls determine handling protocols, with air monitoring and personnel exposure tracking. External standards and regulatory requirements drive update cycles for occupational health protection, reviewed annually or as required by process changes.
Manufacturing Omeprazole Enteric-coated Capsules involves multi-stage synthesis, pelletization, and enteric coating. Capacity scales based on reactor volume, granulation line throughput, and coating facility reliability. In regions with established pharmaceutical parks, average monthly output can often be increased within one to two quarters to meet demand surges, subject to regulatory clearance and availability of qualified starting materials. Availability fluctuates seasonally with API supply, excipient procurement cycles, and maintenance shutdowns.
Lead time depends on batch release timelines aligned with cGMP-compliance, internal stability holding, and final regulatory sampling. Typical commercial shipments are scheduled with a 4–8 week window from order confirmation, though specific lead times depend on variant, regulatory dossier status, and customer audit schedules. MOQ reflects batch scale: larger clients favor full commercial-scale lots, while smaller requests are filled based on secondary splitting logistics and risk-sharing for custom regulatory labels.
Packaging choices revolve around moisture barrier, photostability, and transport risk profile. Bulk capsules are shipped in sealed double-polyethylene-lined HDPE drums for distribution centers, while finished, patient-ready packs (blistered or bottled) depend on destination market standards and the final consumer label. Compliance packaging is required for certain regulated suppliers, and configuration is defined by the end customer and local registration.
Standard INCO terms include FOB, CIF, and DAP, with cold-chain or ambient logistics selected based on label stability data and destination climate. Payment terms, via L/C or net transfer, depend on client track record and export credit insurance, with tighter conditions on first transactions or markets with volatile currency and regulatory environments.
Omeprazole cost structure centers on API synthesis, which is sensitive to up-stream intermediate purity, catalytic conversion yield, and cost of protected intermediates. Primary price drivers include source of benzimidazole intermediates, cost of organic solvents (dichloromethane, acetonitrile), and palladium-based catalysts. Excipient price shifts (e.g. HPMC, enteric polymers) often follow petrochemical indices. Energy intensity of multi-step crystallization and environmental treatment investments weigh into manufacturing cost.
Volatility in raw material pricing traces to upstream fluctuations in international markets for pharmaceutical chemicals. Temporary supply blockages—caused by environmental shutdowns in China or export restrictions in India—ripple rapidly through the cost structure. Grade purity requirements for EU and US registrations create procurement pressure for compliant materials, shifting costs upwards as demand for qualified sources grows. Certification renewals or loss of GMP status at upstream plants also cause sharp price adjustments mid-contract cycle.
Price structures reflect three dominant variables: product grade (OTC, prescription, reference listed drug), purity thresholds (as per pharmacopeial monographs), and depth of analytical data (CoA, method validation, stability). Product batch price increases significantly when customer projects require EUGMP or USDMF-backed lots, full traceability, or custom labeling. Each tier–from local markets to ICH-regulated supply–comes with escalating analytical, batch, and documentation costs. Packaging format (bulk vs. finished) and required certification carry direct impact on final sale price, particularly in serialized, childproof, or specialty containment.
Current supply chains span India, China, Europe, and the United States, with regional specialization based on API manufacturing cost and downstream regulatory compliance. Demand has stabilized as omeprazole remains a front-line proton pump inhibitor, though competition from branded counterparts and generics constrains growth. Supply constraints traced to environmental regulation in Chinese pharmaceutical zones and evolving audit requirements have triggered brief price spikes and allocation events, especially for qualified pharmaceutical ingredients.
United States and EU draw on internal manufacture for regulated supply but depend on India and China for API. Japanese market places highest regulatory scrutiny on trace contaminant control, translating to a premium for Japanese Pharmacopoeia-grade product. Indian capacity, both for API and finished dosage, is expanding in response to Western contract manufacturing demand. China remains the largest supplier of bulk intermediates but faces periodic output interruptions due to stricter green manufacturing enforcement.
Forecasting into 2026, price trends reflect ongoing energy input costs, stricter environmental control in API source countries, and evolving pharmacopoeial standards. Cost base for regulatory-compliant material will increase as long as audit frequency, serialization, and data integrity enforcement expand. Generic competition is expected to limit price escalations in non-regulated markets. In regulated geographies, raw material visibility constraints and secondary packaging complexity will drive moderate year-on-year price increases.
Forecast methodology references internal production cost models, upstream raw material market indices, external audit scheduling data, public pharmacopoeial updates, and customer demand trend analysis. Data sources include published government statistics, international trade flows, and third-party procurement benchmarking where available. Price forecasts reflect input both from proprietary order flow experience and consolidated industry reporting.
Environmental enforcement cycles in China have tightened permitted output for key API intermediates, triggering global supply adjustment. Recent shifts in Indian API policy, narrowing allowable solvents and increasing wastewater treatment oversight, have nudged API production costs higher. Western markets show rising batch rejection rates due to enhanced nitrosamine scrutiny, forcing upstream changes in intermediate selection and batch segregation for exports.
The latest regulatory bulletins in the US and EU call for validated methods for trace-level impurities (especially nitrosamines). Analytical method upgrades and additional batch release testing, along with implementation of advanced serialization on finished products, have become critical in retaining export approval. Audit intervals for key suppliers in the API chain are shortening as authorities increase in-person inspections.
Manufacturers have responded with investments in distributed sourcing for vulnerable intermediates, ramped up in-process monitoring, and enhanced supplier qualification. Contingency stocks in API and auxiliary excipients are being maintained to absorb short-term upstream disruption. Close engagement with regulatory bodies ensures prompt adaptation of process and analytical changes necessary to maintain ongoing product registration and market listing status.
Across the pharmaceutical sector, Omeprazole Enteric-coated Capsules serve a primary role in oral solid dosage form manufacturing for therapies addressing gastric acid-related conditions. The main demand originates from generic and branded drug producers targeting prescription and over-the-counter market segments. Contract manufacturing organizations (CMOs) and hospital compounding units also draw on specific grades for either direct packaging or formulation into custom capsules.
Beyond finished pharmaceuticals, certain research and development labs source production grades for formulation screening, process development, and bioequivalence studies. Any change from prototype to commercial launch in these settings draws attention to properties like dissolution profile, pellet consistency, and release profile under varied pH conditions.
| Application | Typical Grade | Key Selection Criteria |
|---|---|---|
| Branded/Generic Rx Capsules | Pharmaceutical Grade (EP/USP/JP compliant) | Meets monograph assay, low related substances, enteric protection assurance, batch-to-batch reproducibility |
| OTC Capsule Products | Pharmaceutical Grade, standard or customized specification | Consistent dissolution profile, low residual solvents, allergen control, label claim compliance |
| Formulation R&D / Bioequivalence | Development Grade (pilot/validation) | Tunable pellet size distribution, robust processability, certificate of analysis history, technical support for scale-up |
| Compounding / Clinical Evaluations | Small-volume Clinical Grade | Short lead time, traceable lot history, flexible packaging formats, rapid documentation |
Assay and related substances rank as primary control points in all regulated markets. For branded and generic production, impurity profile—including sulfone and desmethoxy impurities—requires analytical confirmation for every batch release. Enteric-coating integrity undergoes acid dissolution and buffer resistance trials: exposure in 0.1N HCl should show negligible drug release. Pellet size, coating thickness, and polymer selection often diverge by customer formulation requirements.
Residual solvents depend on the synthetic route and solvents used in final purification or pelletization. Each lot must demonstrate compliance with established pharmacopeial, regional, or customer-specified limits. Sometimes, distinctions arise between export-only and local market needs—such as for Taiwan FDA, US FDA, or EMA requirements—so grade should align with the intended destination.
Humidity and thermal stability become relevant in tropical and high-humidity transport or warehousing scenarios. We recommend controlling both in the plant and selecting packaging adapted to distribution risk.
Determine if the formulation is intended for prescription, over-the-counter, R&D, or compounding. Demand for global distribution or hospital-only supply can alter the grade and documentation package required. Clearly specifying the final dosage form (capsule, multiparticulate, sachet) helps in narrowing the optimal process route and batch characteristics.
Regulatory filing dictates most grade selection decisions. For regulated markets like Europe, Japan, and the US, confirm monograph compliance and confirm if a DMF (Drug Master File) or CEP (Certificate of Suitability) is required for registration. Local pharmacopoeia alignment and additional risk assessment for nitrosamines and elemental impurities increasingly influence grade acceptance.
For clinical and commercial launches, insist on traceable impurity profiling—especially for known process- or storage-related degradants. Assay values and main related substance acceptance criteria align with batch release protocols. Lower impurity specs—such as for pediatric or sensitive patient formulations—require additional purification investment and have different process control triggers.
High-volume capsule production often favors bulk grades in commercial packaging, linked to stable long-term supply and predictable pricing. R&D, clinical, or low-volume buyers may request flexible lot sizes and customized documentation, with corresponding cost and lead time adjustments. Larger orders may benefit from plant scheduling for dedicated campaigns; smaller lots may be packaged off major lines.
Product validation in the formulators’ own system remains central for both technical fit and regulatory assurance. Request production-scale samples, along with full batch history and release documentation. Comparative dissolution, impurity, and handling tests on-site or at a contract lab can flag compatibility or highlight adjustment needs for excipient blend, pellet uniformity, or enteric coating thickness.
As a producer of omeprazole enteric-coated capsules, operations run under a comprehensive quality infrastructure suited for regulated pharmaceutical manufacturing. Management systems reflect ongoing pharmaceutical GMP certification, with audit trails for each production campaign. Facility certifications are tailored for export markets, and each line undergoes routine audits by national and international regulatory teams. Dedicated quality staff oversee batch segregation, environmental monitoring, and cross-contamination risk mitigation. Ongoing verification aligns process documentation to both ICH and PIC/S standards, which evolve based on site-specific regulatory acceptance in target markets.
Batch release incorporates compliance to pharmacopoeial monographs (such as USP, EP, or region-specific standards), where specifications depend on declared grades and regional healthcare authority registration. Certification scope addresses particle size distribution for enteric granules, delayed-release performance, and specified degradation profiles. Impurity thresholds and active content uniformity align with the grade supplied, as referenced in the approved registration dossier. Any modifications or process changes trigger a certification review, documented in the certificate of analysis (COA) and certificate of compliance (COC) supplied with each batch.
Each batch ships with a full technical dossier, comprising manufacturing record, critical control point summaries, analytical data sets, and release documentation. Product traceability connects raw material input, intermediate handling, and the final packaging record. Standard documentation includes batch production records, validated test method reports, and summaries of OOS/OOT investigations, when applicable. Regulatory and client audits guide document retention periods and reporting protocols. On request, data on process validation, stability studies, or impurity trend tracking can be supplied within confidentiality frameworks dictated by mutual non-disclosure agreements.
Production scheduling is built on the principle of continuous supply and redundancy across key unit operations. Demand signals from regular clients receive priority allocation in production cycles, and contingency planning addresses fluctuations in upstream material supply chains. Flexible contract terms are discussed openly, designed around customer ordering cycles, inventory needs, and region-specific market access timelines. For project-based orders, options for forward manufacturing slots or safety stock holding can be arranged, guided by projected offtake and mutual forecast accuracy.
Manufacturing volumes for omeprazole capsules reflect long-term investment in scalable process trains and validated batch reactors. Capacity expansion follows a modular logic, with additional lines commissioned as bulk procurement partners increase volume. Buffer inventory is managed based on historic consumption rates, risk-adjusted for raw material lead times and regulatory release cycles. Cross-site redundancy supports supply continuity against single-point production risks.
Sample requests are reviewed by a dedicated technical-commercial interface. Full documentation accompanies each sample dispatch, including manufacturing date, batch trace, and analytical summary. Clients engaged in registration or process transfer activities may request tailored sample lots, with documentation aligned to their submission or scale-up requirements. Feedback from sampling supports internal process refinement and client-specific adjustment of granule size distribution, coating uniformity, or packaging.
Business cooperation adapts to the technical and operational needs on both sides. Options include consignment inventory, call-off orders, rolling supply agreements, or just-in-time production triggers. Long-term supply memoranda align quality management activities between both parties, streamlining deviation handling and audit response. Adjustment of packaging configuration, shipment frequency, or technical specification is negotiated directly with partner QA and procurement teams. Strategic partnerships may include technical support for dossier preparation or submission assistance for new market entry.
Production of omeprazole enteric-coated capsules requires a multi-faceted approach. Industrial scale-up brings up several key questions. Formulators increasingly examine the selection of API particle size distribution and excipient compatibility to reduce degradation during processing. Encapsulation efficiency and coating uniformity drive research in film-forming polymer selection, especially for acid-sensitive APIs like omeprazole. Quality teams notice that small differences in raw material batch quality or moisture exposure can produce variability in release performance and stability profiles.
Efforts in R&D now focus on enteric coating integrity, moisture barrier effectiveness, and non-solvent-based coating systems. Manufacturers track process deviations—such as granulation endpoint, drying time, and residual solvent content—since these factors alter the dissolution profile. Techniques for minimizing batch-to-batch error remain hot topics, especially where regulatory filings emphasize lot traceability and reproducibility.
Healthcare delivery shifts have expanded interest in high-strength capsule formats, dual-release systems, and pediatric-friendly dosage forms. Client requests reflect demand for smaller capsule formats with tailored release kinetics. Veterinary applications and regional regulatory harmonization also drive customized specification projects.
Omeprazole degrades quickly in acidic and humid environments, making robust encapsulation and storage systems essential. Stability challenges tie directly to film coating uniformity and minimal pinhole formation. Manufacturing teams see that specific coating polymer selections, such as acrylic vs. cellulose, yield distinctly different stability and dissolution profiles across climates. New breakthroughs examine aqueous-based coating systems to reduce solvent emissions and contamination risks, but maintaining coating quality without organic solvents remains a high bar. Process engineering groups actively troubleshoot pan speed, spray rate, and fluidized bed parameters to prevent agglomeration and ensure reproducible mass transfer.
Global demand for omeprazole enteric-coated capsules should keep rising, especially where patent expiration has increased generics manufacturing. Volume growth remains highest in emerging markets, with most premium-grade projects focusing on robust shelf life and cold-chain-independent distribution. Regulatory harmonization in large markets like the EU and China shapes requirements for multi-source registration, which in turn puts pressure on consistency in product release standards.
Production technology trends move toward continuous processing and more advanced in-line monitoring of coating and content uniformity. Manufacturers investing in automation and digital batch record systems consistently see greater yield and fewer out-of-spec deviations. A shift toward robot-assisted handling aims to reduce operator exposure to micronized API dust, improving workplace safety and maintaining regulatory compliance for airborne particulates.
Solvent recovery and reduction get priority in plant upgrades. Many sites transition to fully aqueous-based coating formulations, analyzing trade-offs for process control and capsule hardness. Sourcing sustainably produced excipients, especially for high-volume sugar spheres and coating agents, drives collaboration with upstream suppliers. Residue minimization and wastewater management systems become central design considerations. Sustainability metrics increasingly involve assessment of end-to-end carbon footprint for each formulated lot.
Technical teams provide direct feedback on excipient-API compatibility, capsule filling uniformity, coating process troubleshooting, and in-process stability monitoring. Staff engineers guide end users through optimal process route selection based on existing equipment and regulatory target markets. Support includes analytical method transfer, validation documentation, impurity profile analysis, and assistance with regulatory query responses for registration dossiers.
Clients routinely need guidance to match API particle grade, capsule size, and coating weight to their downstream packaging and labeling systems. For large-scale adopters, detailed engineering run data helps tailor process parameters—especially for fluid bed vs. pan coating equipment. The technical department works alongside quality assurance to assess product behavior under various stress storage conditions and recommend solutions for moisture or light sensitivity.
The commitment extends beyond initial delivery. If any lot deviates from agreed parameters, quality and technical teams investigate the root cause with full transparency. Data collected during production and storage supports timely resolution, whether issues involve capsule brittleness, failure in dissolution, or unexpected impurity signals. For international shipments, handover includes stability data and region-specific compliance support. Customer feedback gets funneled into the next round of process optimization, ensuring continuous improvement across both manufacturing and supply.
As a direct producer of Omeprazole enteric-coated capsules, our operation spans from active pharmaceutical ingredient synthesis through to encapsulation and final packaging. Our teams monitor each batch in-house, supporting critical consistency in release profiles and dose strength. Every lot meets the finished specifications detailed in international pharmacopeias, confirmed through our own validated analytical procedures. From mixing to finished capsules, we control the production environment, ensuring reproducibility for customers who manage regulated portfolios.
Pharmaceutical formulators select Omeprazole from our catalog to manufacture prescription and over-the-counter products targeting gastric acid conditions. Contract manufacturers, hospital supply chains, and branded generic divisions rely on reliable capsule performance for high-volume runs. These capsules serve as a staple input for treatment programs in institutional healthcare and mass-market retail outlets.
Our facility operates with documented process parameters monitored throughout the line. Critical control points track particle size, enteric coating integrity, and dissolution rates—plus visual checks for capsule defects. Finished goods must pass dissolution and potency assays performed in-house, rather than relying on spot-testing or random sampling. All analytical records, from raw materials to final release, are archived electronically for audit readiness.
We fill and seal Omeprazole capsules in blister and bulk pack options, designed for both clinical and commercial packing lines. Export and domestic deliveries ship in reinforced cartons with tamper-evident features and clear traceability markers stamped by our internal QA unit. Automated counting and sealing lines drive faster output for industrial-scale requirements. Logistic partners collect orders directly from our warehouse, supporting scheduled delivery commitments even through seasonal demand spikes.
Our technical team works with procurement and regulatory staff at the customer’s end, providing full batch documentation, compliance support, and stability data required by their own authorities. Process engineers and QA managers at our plant answer specification questions, manage deviation reports, and coordinate customer audits. Troubleshooting support and product performance briefings are available throughout project timelines for both pipeline launches and routine supply.
Direct manufacturing offers buyers assurance on traceability, fast documentation turnaround, and transparent batch reporting. Large-scale users consolidate their purchasing footprint, minimizing risk linked to re-batching or offshore relabeling. Cost control stems from streamlined packaging operations, reduction in intermediary handling, and the ability to reserve future output through volume-based scheduling. Supply chain managers benefit from stable pricing and prioritized allocation for long-term contracts, reducing the chance of service interruptions.
By maintaining oversight of the full production chain, we provide industrial customers with Omeprazole capsules designed, produced, and packed for reliability in regulated environments. Our aim remains: consistent delivery to specification, informed technical backing, and supply chain security for business-critical use.
We manufacture Omeprazole enteric-coated capsules in our facility with full focus on delivering both chemical stability and intended therapeutic action. Omeprazole belongs to the class of proton pump inhibitors; it suppresses gastric acid secretion by targeting the H+/K+-ATPase enzyme system present in the parietal cells of the stomach lining. This enzyme system catalyzes the final step in acid production. Omeprazole forms a covalent bond after getting activated in acidic conditions, leading to long-lasting inhibition of acid output in the stomach.
Our process consistently produces Omeprazole that remains non-ionized and stable until it reaches the parietal cell canaliculi, where acidic hydrogen ions trigger activation. This targeted inhibition proves especially beneficial to patients suffering from GERD, peptic ulcers, and other acid-related gastrointestinal diseases. From years of production experience, we see real impact when matching enteric protection with predictable release profiles.
Omeprazole degrades rapidly when exposed to gastric acid, so simple tablets or uncoated capsules cannot deliver the intended therapeutic benefit. Our enteric coating technology shields the active compound as it passes through the highly acidic stomach. The coating itself uses specialized polymers designed to resist dissolution at low pH but dissolve at the higher pH found in the upper small intestine.
This approach preserves the functional integrity of Omeprazole through the initial gastric phase. Experience on our coating lines shows that consistent film thickness, complete coverage, and tight process controls produce capsules with highly reproducible pH-triggered release. Rigorous in-process testing forms part of every batch we ship, ensuring the medication survives stomach conditions and delivers Omeprazole where it works best.
Our dissolution profile is not just a regulatory checkbox—it reflects the result of well-engineered formulation and controlled manufacturing. The enteric-coated capsule stays intact in simulated gastric fluid for no less than two hours, showing negligible Omeprazole release during this phase. Once the capsule reaches a medium of pH above 6, such as simulated intestinal fluid, the coating dissolves within a targeted period, and Omeprazole is released promptly for absorption.
We provide detailed dissolution data for each batch, as consistent release translates directly into consistent therapeutic effect. In our production, deviations in dissolution can arise from raw material variance, film defects, or suboptimal process conditions. We continually invest in analytical equipment and process automation to suppress these risks. For each lot, our QC team monitors release curves using validated USP or pharmacopoeial methods.
Producing an enteric-coated capsule brings unique challenges: raw material quality, granule size distribution, coating uniformity, and the potential for capsule shell rupture under pressure. Drawing from years of plant-floor troubleshooting, we maintain close control over raw material suppliers and use in-line monitoring to catch coating defects before final packaging. Our team collaborates directly with formulation chemists and coating specialists to refine every production run.
By acting on real-time data, our factory can align product performance with both pharmacopoeial standards and the clinical expectations of the medical community. To the end user, this means Omeprazole capsules that perform as promised—delivering targeted acid suppression, optimized therapeutic results, and reliable stability from our factory to the pharmacy shelves.
Production of Omeprazole Enteric-coated Capsules on a commercial scale relies on a tightly controlled workflow. Our factory produces encapsulated forms using imported pelletized Omeprazole, high-barrier excipients, and robust enteric coatings to maintain integrity against gastric acid. Bulk buyers approach us to secure reliable, consistent sources at scale, but large volume orders are more than a simple transaction. Balancing material procurement, scheduled batch runs, quality control, and regulatory documentation calls for a systematic approach to quoting lead times and minimum order quantities.
Our process is optimized for industrial-scale operations, not retail increments. To launch a batch, we require a full shift on our encapsulation lines: this means a minimum run of a few million capsules per lot to optimize labor and raw material usage. Less than this and the cost per capsule jumps, waste rises, and machinery sits idle after shorter cycles. Our MOQ for Omeprazole Enteric-coated Capsules reflects actual production economics — keeping the order size at the level necessary for automated capsule filling, in-line coating, sampling, and validated packaging.
Lab runs or test batches don't meet commercial GMP requirements or offer the repeatability clients depend on. A full production run ensures each lot goes through full-stage in-process QC: every shift batch undergoes disintegration, acid-resistance, and content uniformity testing in our own laboratories. This also allows seamless integration with our standard packaging lines, reducing the risk of cross-contamination and simplifying traceability.
Lead time is not simply a matter of making capsules and shipping boxes out the door. We coordinate raw material deliveries weeks in advance, especially for pharmaceutical-grade excipients and active ingredients. Once materials clear quality checks, we schedule the batch slot, factoring in current line occupancy, mandatory cleaning, and calibration between different products.
Each production run covers mixing, pelletizing, enteric coating, drying, and encapsulation, ending with bulk or blister packaging. Every batch undergoes full microbiological and chemical analysis before release. Documentation packets accompany each shipment, matching local and international pharmaceutical standards. The complete cycle—from order confirmation, scheduling, production, through to analytical testing—typically requires several weeks. Any order that includes special packaging, branded labels, or customized documentation may need additional days.
Bulk procurement for Omeprazole Enteric-coated Capsules is not just an exchange—it's an ongoing collaboration. Our team works directly with procurement managers, regulatory specialists, and technical officers from each client. Typical minimum order quantities reflect our standards for efficiency and stability, backed by proven batch records and compliance assurance. Our logistics coordinators handle temperature-sensitive shipments with pharmaceutical-grade monitoring to preserve product quality in transit, regardless of destination.
We offer technical consultations to review any special requirements, coordinate multi-lot shipments, or synchronize re-order schedules. Our aim is to deliver not just product but peace of mind, combining scale with full traceability and local documentation. Successful bulk partnerships grow through trust, transparency, and continuous improvement—principles that have carried our operations across domestic and international markets for two decades.
As a manufacturer producing Omeprazole enteric-coated capsules, we constantly face evolving regulations in global target markets. Authorities demand clear documentation: market authorization, certificates of analysis, batch release records, GMP compliance, and stability data. Our regulatory affairs specialists track updates from each destination—whether in Southeast Asia, Europe, Africa, or the Americas—because requirements can shift without much notice. For example, some countries require the submission of full excipient disclosure, impurity profiles, and updated pharmacopoeial compliance, while others focus on audit certificates, import permits, or serialization protocols. We make a point to test every batch for quality standards set by the major pharmacopoeias, including the USP and EP, and we retain batch samples for potential inspection after shipment. Our data-driven approach covers stability, dissolution, and content uniformity testing before capsules clear the final packaging step.
Ongoing engagement with local health authorities delivers smoother import clearance. Batch traceability supports turnaround time at port authorities. All dossiers and certificates are maintained in original and translated formats as needed. Where a country implements new serialization, we upgrade our labeling processes accordingly—using either unit-level or shipper-level coding, sometimes both, with real-time data printed at the line. Some markets now require environmental safety data or child-resistant packaging, which gets incorporated into our design and submission cycles.
Reliable transit storage keeps omeprazole protected from degradation. This drug class is sensitive to moisture, heat, and light—so our capsules must stay inside the validated packaging throughout shipment. We use high-barrier aluminum-aluminum blisters or double-aluminum strips. Bulk capsules are double-bagged in LDPE liners with desiccant pouches, then packed in thick-wall HDPE drums to prevent exposure. All outbound shipments use temperature-validated data-logger sets. Our shipping instructions state that storage between 15–25°C preserves active content for the entire transit period, which aligns with standard “room temperature” guidelines recognized by most regulatory authorities. Excursions beyond 25°C, even for a day, increase the risk of hydrolysis or color change, so our logistics partners always follow these parameters using insulated containers or climate-controlled trucks and air freight holds during summer transitions.
We advise that capsules never be kept in direct sunlight or in conditions exceeding 60% relative humidity. Shipping operations leave little room for chance, so confirmation photographs of tamper-evidence, batch identification, and temperature readings accompany every delivery. The supply chain protocol includes sealed containers, temperature monitors, and arrival inspection at the destination warehouse: if a data-logger records a spike, that batch is quarantined for retest before distribution. We take pride in offering real-time support—our QC and QA teams track samples and handle reclamation if an excursion occurs.
Strict import compliance and attention to protective transit storage keep our omeprazole capsules trusted in the marketplace. Our technical documentation and shipping controls stay updated as regulations and customer expectations progress. Experience shows that these details define the reliability of each shipment—and ultimately everyone's health outcomes. We remain committed to transparency and open technical support; our teams stay ready to provide regulatory or transit evidence to importers, health authorities, and long-term pharmacy partners.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
